EMINA EFENDIC: Open Payments
NPI 1093363301 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,294 in 15 payments from 9 companies in 2025. Trend: 2023 $383 · 2024 $1,298 · 2025 $1,294
Food & beverage: $1,294
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $242 |
| Axsome Therapeutics, Inc. | 2 | $237 |
| E.R. Squibb & Sons, L.L.C. | 4 | $158 |
| Janssen Pharmaceuticals, Inc | 2 | $143 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| ABBVIE INC. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| Alkermes, Inc. | 1 | $121 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
Products named: CAPLYTA, Auvelity, COBENFY, INVEGA SUSTENNA, FANAPT, VRAYLAR, ABILIFY MAINTENA, LYBALVI.
Industry payments across CT — which companies pay providers there.
